Medicine and Dentistry
Malignant Neoplasm
100%
Abdominal Cancer
60%
Colorectal Carcinoma
47%
Overall Survival
45%
Cancer Pain
44%
Breast Cancer
41%
Metastatic Colorectal Cancer
36%
Adjuvant Chemotherapy
29%
Life Sustaining Treatment
29%
Disease
26%
Crohn's Disease
22%
Decision Making
22%
Second-Line Chemotherapy
22%
Fluorouracil
20%
Docetaxel
18%
Recurrent Disease
17%
Oxaliplatin
17%
Cisplatin
17%
Adjuvant Therapy
17%
Cancer Staging
16%
Neoplasm
16%
Cyclophosphamide
16%
Doxorubicin
16%
Epidermal Growth Factor Receptor 2
15%
Gamma Urogastrone
15%
Non Small Cell Lung Cancer
15%
Adenocarcinoma
15%
Tumor Necrosis Factor
15%
Informed Consent
15%
Lymph Node
14%
Recurrence Free Survival
14%
Thrombus
14%
Breakthrough Pain
14%
Arthralgia
14%
Smouldering Myeloma
14%
Synapsin I
14%
Moxibustion
14%
Retrospective Cohort Study
14%
Cancer-Related Fatigue
14%
Aortic Thrombosis
14%
Small Cell Lung Cancer
14%
Primary Tumor
14%
Base Excision Repair
14%
Ginseng
14%
Traditional Herbal Medicine
14%
Neoadjuvant Chemotherapy
14%
Acute Myeloid Leukemia
14%
Tumor Necrosis Factor Receptor
14%
Acute Promyelocytic Leukemia
14%
Meta-Analysis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
80%
Abdominal Cancer
53%
Overall Survival
39%
Metastatic Colorectal Cancer
36%
Cancer Pain
36%
Breast Cancer
23%
Second-Line Chemotherapy
22%
Docetaxel
18%
Neoplasm
18%
Colorectal Carcinoma
17%
Cisplatin
17%
Fluorouracil
17%
Oxaliplatin
17%
Doxorubicin
16%
Cyclophosphamide
16%
Adenocarcinoma
15%
Observational Study
15%
Disease
14%
Aortic Thrombosis
14%
Thrombus
14%
Gamma Urogastrone
14%
Cohort Study
14%
Small Cell Lung Cancer
14%
Synapsin I
14%
Enoxaparin
14%
Epidermal Growth Factor Receptor 2
14%
Primary Tumor
14%
Tumor Necrosis Factor Receptor
14%
Non Small Cell Lung Cancer
14%
Acute Myeloid Leukemia
14%
Disease Free Survival
14%
Progression Free Survival
12%
Colon Carcinoma
11%
Recurrent Disease
11%
Hormone Receptor
11%
Survival Rate
11%
Recurrence Free Survival
9%
Multidrug Resistance
8%
Irinotecan
8%
Oxycodone
8%
Adverse Event
7%
Physical Disease by Body Function
7%
Antiemetic Agent
7%
Pembrolizumab
7%
Eaton Lambert Syndrome
7%
Diffuse Large B Cell Lymphoma
7%
Myelodysplastic Syndrome
7%
Imatinib
7%
Neuropathic Pain
7%
Stomach Adenocarcinoma
7%
Nursing and Health Professions
Malignant Neoplasm
74%
Cancer Pain
45%
Quality of Life
26%
Prospective Cohort Study
22%
Advanced Cancer
22%
Abdominal Cancer
22%
Disease
21%
Palliative Therapy
20%
Life Sustaining Treatment
15%
Cancer Staging
15%
Confidence Interval
14%
Patient Education
14%
Adjuvant Chemotherapy
14%
Aromatase Inhibitor
14%
Cohort Analysis
14%
Economic Evaluation
14%
Breakthrough Pain
14%
Health Economics
14%
Breast Cancer
14%
Arthralgia
14%
Meta Analysis
14%
Oncologist
10%
Care Group
9%
Cancer Therapy
9%
Odds Ratio
9%
Student T Test
7%
Patient Referral
7%
Physical Disease by Body Function
7%
Cancer Pain Management
7%
Pilot Study
7%
Laboratory Test
7%
Metastatic Colorectal Cancer
7%
Psychometry
7%
Adjuvant Therapy
7%
Acute Myeloid Leukemia
7%
Myelodysplastic Syndrome
7%
Non Small Cell Lung Cancer
7%
Elderly Patient
7%
MDS1 and EVI1 Complex Locus Protein
7%
Neuropathic Pain
7%
Homeopathy
7%
Brief Pain Inventory
6%
Fisher Exact Test
6%
Disease Free Survival
5%
Irinotecan
5%
Drug Therapy
5%
University Hospital
5%
